- RecruitingPHASE3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
This study is testing a new drug, linvoseltamab, for multiple myeloma that has returned or needs re-treatment. It compares linvoseltamab to a standard three-drug combination (elotuzumab, pomalidomide, and dexamethasone) to see which works better and has fewer side effects.
For: Relapsed Refractory Multiple Myeloma (RRMM)United States · Australia · Belgium - RecruitingPHASE1, PHASE2
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
This study is testing two experimental drugs, REGN7945 and linvoseltamab, for advanced multiple myeloma that has come back. We want to see if combining them is safe and helps more than linvoseltamab alone.
For: Relapsed/Refractory Multiple MyelomaAustralia · United Kingdom - RecruitingPHASE1, PHASE2
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
This study is testing a new drug, linvoseltamab, for people recently diagnosed with multiple myeloma who haven't had treatment yet. We want to see if it's safe, how well it works toshrink the cancer, and what the best dose is.
For: Multiple MyelomaUnited States · France · Spain - RecruitingPHASE3
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
This study is testing a new drug, linvoseltamab, for people with a type of blood cancer called multiple myeloma. It compares this new drug to standard treatments to see how safe and effective it is, for patients who cannot have a stem cell transplant.
For: Multiple MyelomaAustralia · Austria · Croatia - RecruitingPHASE3
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
This study looks at a new drug, linvoseltamab, for multiple myeloma that has come back or isn't responding to treatment. It compares linvoseltamab alone or with another drug, carfilzomib, against standard treatments to see if it's safer and works better.
For: Relapsed and/or Refractory Multiple Myeloma (RRMM)United States · Australia · Brazil - RecruitingPHASE1, PHASE2
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
This study is testing a new medicine called linvoseltamab for adults with multiple myeloma that hasn't responded to other treatments. We want to find the safest and most effective dose, understand its side effects, and see if it can help treat the cancer.
For: Multiple MyelomaUnited States · Belgium · Germany - RecruitingPHASE3
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
This study looks at two different drugs, linvoseltamab and daratumumab, for people with a condition called High-Risk Smoldering Multiple Myeloma (HR-SMM). Doctors want to find out if linvoseltamab is better at stopping this condition from turning into active Multiple Myeloma, a type of blood cancer.
For: High Risk Smoldering Multiple Myeloma (HR-SMM)United States · Japan · South Korea - RecruitingPHASE1, PHASE2
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
This study is testing a new medicine called linvoseltamab for people with a rare condition called AL amyloidosis. We want to see if it's safe and if it can help people whose condition has come back or who haven't responded to other treatments.
For: Relapsed/Refractory Systemic Light Chain AmyloidosisUnited States · Greece · South Korea